Ou Zhanhui, Du Jing, Liu Nengqing, Fang Xiaowu, Wen Xiaojun, Li Jieliang, Lin Xiufeng
Reproductive Medicine Center, Boai Hospital of Zhongshan Affiliated to Southern Medical University, 6 Chenggui Road, East District, 528400, Zhongshan, China.
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Contracept Reprod Med. 2024 Aug 26;9(1):41. doi: 10.1186/s40834-024-00303-w.
To investigate the association between a low oocyte maturity ratio from in vitro fertilization cycle and blastocyst euploidy.
A total of 563 preimplantation genetic testing (PGT) cycles (PGT cycles with chromosomal structural rearrangements were excluded) were performed between January 2021 and November 2022 at our center (average oocyte maturity rate: 86.4% ± 14.6%). Among them, 93 PGT cycles were classified into the low oocyte maturity rate group (group A, < mean - 1 standard deviation [SD]), and 186 PGT cycles were grouped into the average oocyte maturity rate group (group B, mean ± 1 SD). Group B was 2:1 matched with group A. Embryological, blastocyst ploidy, and clinical outcomes were compared between the two groups.
The oocyte maturity (metaphase II [MII oocytes]), MII oocyte rate, and two pronuclei (2PN) rates were significantly lower in group A than in group B (5.2 ± 3.0 vs. 8.9 ± 5.0, P = 0.000; 61.6% vs. 93.0%, P = 0.000; 78.7% vs. 84.8%, P = 0.002, respectively). In group A, 106 of 236 blastocysts (44.9%) that underwent PGT for aneuploidy were euploid, which was not significantly different from the rate in group B (336/729, 46.1%, P = 0.753). However, euploid blastocysts were obtained only in 55 cycles in group A (55/93, 59.1%), which was lower than the rate in group B (145/186, 78.0%, P = 0.001). The clinical pregnancy rate in group B (73.9%) was higher than that in group A (58.0%) (P = 0.040).
Our results suggest that a low oocyte maturity ratio is not associated with blastocyst euploidy but is associated with fewer cycles with euploid blastocysts for transfer, lower 2PN rates, and lower clinical pregnancy rates.
探讨体外受精周期中低卵母细胞成熟率与囊胚整倍体之间的关联。
2021年1月至2022年11月在本中心共进行了563个植入前基因检测(PGT)周期(排除染色体结构重排的PGT周期)(平均卵母细胞成熟率:86.4%±14.6%)。其中,93个PGT周期被分为低卵母细胞成熟率组(A组,<平均值-1标准差[SD]),186个PGT周期被分为平均卵母细胞成熟率组(B组,平均值±1 SD)。B组与A组按2:1匹配。比较两组的胚胎学、囊胚倍性和临床结局。
A组的卵母细胞成熟度(中期II[MII卵母细胞])、MII卵母细胞率和双原核(2PN)率均显著低于B组(5.2±3.0对8.9±5.0,P = 0.000;61.6%对93.0%,P = 0.000;78.7%对84.8%,P = 0.002)。在A组中,236个接受非整倍体PGT的囊胚中有106个(44.9%)为整倍体,与B组的比例(336/729,46.1%)无显著差异(P = 0.753)。然而,A组仅在55个周期中获得了整倍体囊胚(55/93,59.1%),低于B组(145/186,78.0%,P = 0.001)。B组的临床妊娠率(73.9%)高于A组(58.0%)(P = 0.040)。
我们的结果表明,低卵母细胞成熟率与囊胚整倍体无关,但与可用于移植的整倍体囊胚周期数减少、2PN率降低和临床妊娠率降低有关。